Emerson (NYSE:EMR) Keeps Guidance Conservative

Emerson (NYSE:EMR) has kept their guidance going into 2011 conservative even though they reported strong orders for November.

Barclays (NYSE:BCS) noted, "Emerson reported strong November orders but reiterates conservative guide: EMR reported sustained order strength last month, with 3-month avg. orders up 15-20% (flat with Sept & Oct)...We have taken our 1Q EPS estimate down from $0.72 to $0.67, more in line with the consensus. The year goes to $3.30, still above the $3.26 consensus."

Barclays reiterates an "Overweight" on Emerson, which closed Monday at $57.89, down $0.44, or 0.75 percent. Barclays has a price target of $67 on them.